Antiprotozoal agents: An overview

Anti-Infective Agents in Medicinal Chemistry

Volumn 8, Issue 4, 2009, Pages 345-366

  Graebin, C S ^a   Uchoa, F D ^a   Bernardes, L S C ^b   Campo, V L ^b   Carvalho, I ^b   Eifler Lima, V L ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; 2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; ALBACONAZOLE; AMANTADINE DERIVATIVE; AMODIAQUINE; ANTIPROTOZOAL AGENT; BENZNIDAZOLE; CHLOROQUINE; EFLORNITHINE; FOSMIDOMYCIN; IMIQUIMOD; MEFLOQUINE; MEGLUMINE ANTIMONATE; MELARSOPROL; MILTEFOSINE; NIFURTIMOX; NITROFURAL; PENTAMIDINE; POSACONAZOLE; PRIMAQUINE; QUININE; QUINOLINE DERIVATIVE; RAVUCONAZOLE; SIALIDASE INHIBITOR; SITAMAQUINE; STIBOGLUCONATE SODIUM; SURAMIN; TAFENOQUINE; TETRAOXANE DERIVATIVE; UNINDEXED DRUG;

AFRICAN TRYPANOSOMIASIS; AMASTIGOTE; AMNESIA; ANEMIA; ANOREXIA; ANTIMALARIAL DRUG RESISTANCE; BLOOD CLOTTING DISORDER; BONE MARROW DEPRESSION; BRAIN DISEASE; CHAGAS DISEASE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG STRUCTURE; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HALF LIFE TIME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOTENSION; INJECTION SITE PAIN; KIDNEY FAILURE; LEISHMANIASIS; LEUKOPENIA; MALARIA; MALARIA FALCIPARUM; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEPHROTOXICITY; NEURITIS; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; NONHUMAN; PARASITE TRANSMISSION; PERIPHERAL NEUROPATHY; PLASMODIUM BERGHEI INFECTION; PLASMODIUM OVALE MALARIA; PLASMODIUM YOELII INFECTION; REVIEW; SIDE EFFECT; SKIN ALLERGY; SKIN LEISHMANIASIS; SLEEP DISORDER; STOMACH IRRITATION; TREMOR; TRYPANOSOMA CRUZI; TRYPANOSOMA GAMBIENSE; TRYPANOSOMA RHODESIENSE; TRYPOMASTIGOTE; VISCERAL LEISHMANIASIS; VOMITING; WEIGHT REDUCTION;

EID: 73549088553     PISSN: 18715214     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152109789760199     Document Type: Review

References (119)

1. Linares, G.; Ravaschino, E.; Rodriguez, J. Progresses in the field of drug design to combat tropical protozoan parasitic diseases. Curr. Med. Chem., 2006, 13, 335-360.
2. Renslo, R.; Mckerrow, J.H. Drug discovery and development for neglected parasitic diseases. Nat. Chem. Biol., 2006, 2, 701-710.
3. Gascón, J.; Albajar, P.; Canãs, E.; Flores, M.; Gómez, J.; Herrera, P.R.N.; Lafuente, C.A.; Luciardi, H.L.; Moncayo, A.; Molina, L.; Muñoz, J.; Puente, S.; Sanz, G.; Treviño, B.; Salles, X.S. Diagnosis, management, and treatment of chronic Chagas' heart disease in areas where Trypanosoma cruzi infection is not endemic. Rev. Esp Cardiol., 2007, 60, 285-293.
4. Word Health Organization. Reporte del grupo de trabajo científico sobre la enfermedad de Chagas. 2005. WHO: Buenos Aires, 2008.
5. Portela-Lindoso, A.A.B.; Shikanai-Yasuda, M.A. Chronic Chagas' disease: from xenodiagnosis and hemoculture to polymerase chain reaction. Rev. Saúde Pública, 2003, 37, 107-115.
6. Dardonville, C. Recent advances in antitrypanosomal chemotherapy: patent literature. Expert Opin. Ther. Pat,, 2005, 15, 1241-1257.
7. www.fiocruz.br, OCI, 2008.
8. Brand, T.V.; Goble, F.C.; Zeledon, R.; Tejada, C.; Pizzi, T.; Koeberle, F.; de-Freitas, J.L.P.; de-Mello-Deane, L. and Brenner, Z. Pan American Health Organization, 1962, 1.
9. Urbina, J.A. Chemotherapy of Chagas' disease. Curr. Pharm. Des., 2002, 8, 287-295.
10. Coura, J.R.; De Castro, S.L. A critical review on Chagas' disease chemoterapy. Mem. Inst. Osw. Cruz, 2002, 97, 3-24.
11. Cerecetto, H.; Gonzalez, M. Chemotherapy of Chagas' disease: status and new developments. Curr. Top. Med. Chem., 2002, 2, 1187-1213.
12. Ferraz, M.L., Gazzinelli, R.T.; Alves, R.O., Urbina, J.A.; Romanha, A.J. The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. Antimicrob. Agents Chemother., 2007, 51, 1359-1364.
13. Wendel, S.; Gonzaga, A.L. Chagas' disease and blood transfusion: a new world problem? Vox Sanguinis, 1993, 64, 1-12.
14. Urbina, J.A.; Do Campo, R. Specific chemotherapy of Chagas' disease: controversies and advances. Trends Parasitol., 2003, 19, 495-501.
15. Duschak, V.G.; Couto, A.S. An insight on targets and patented drugs for chemotherapy of Chagas' disease. Rec. Pats. Anti-Infect. Drug Disc., 2007, 2, 19-51.
16. Silva, D.T.; de Meirelles, N.; Almeida, D.; Urbina, J.A; Pereira, M.C. Cytoskeleton reassembly in cardiomyocytes infected by Trypanosoma cruzi is triggered by treatment with ergosterol biosynthesis inhibitors. Int. J. Antimicrob. Agents, 2006, 27, 530-537.
17. Urbina, J.A. Specific treatment of Chagas' disease: current status and new developments. Curr. Opin. Infect. Dis., 2001, 14, 733-741.
18. Urbina, J.A.; Payares, G.; Sanoja, C.; Molina, J.; Lira, R.; Brener, Z.; Romanha, A.J. Parasitological cure of acute and chronic experimental Chagas' disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int. J. Antimicrob. Agents, 2003, 21, 39-48.
19. Corrales, M.; Cardozo, R.; Segura, M.A.; Urbina, J.A.; Basombrío, M.A. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease. Antimicrob. Agents Chemother., 2005, 49, 1556-1560.
20. Urbina, J.A.; Payares, G.; Sanoja, C.; Lira, R.; Romanha, A. J. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas' disease. Intl. J. Antimicrob. Agents, 2003, 21, 27-38.
21. Engel, J.C.; Doyle, P.S.; Hsieh, I.; McKerrow, J.H. Cysteine protease inhibitors cure experimental Trypanosma cruzi infection. J. Exp. Med., 1998, 188, 725-734.
22. Barr, S.C.; Warner, K.L.; Kornreic, B.G.; Piscitelli, J.; Wolfe, A.; Benet, L.; McKerrow, J.H. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob. Agents Chemother., 2005, 49, 5160-5161.
23. Ribeirão, M.; Pereira-Chioccola, V.L.; Eichinger, D.; Rodrigues, M.; Schenkman, S. Temperature differences for trans-glycosylation and hydrolysis reaction reveal an acceptor binding site in the catalytic mechanism of Trypanosoma cruzi trans-sialidase. Glycobiology, 1997, 7, 1237-1246.
24. Corey, W.T.; Lima, M.F.; Villalta, F. Trypanosoma cruzi uses a 45-KDa mucin for adhesion to mammalian cells. Biochem. Biophys. Res. Commun., 2002, 290, 29-34.
25. Pereira, V.L.; Serrano, A.; Almeida, I.C.; Rodrigues, M.M. Mucinlike molecules form a negatively charged coat that protects Trypanosoma cruzi trypomastigotes form from killing by human anti-α-galactosyl antibodies. J. Cell Sci., 2000, 113, 1299-1307.
26. Ferrero-Garcia, M.A.; Sanches, D.O.; Frasch, A.C.C.; Parodi, A. The effect of pyridoxal 5'-phosphate and related compounds on Trypanosoma cruzi trans-sialidase. J. An. Asoc. Quim. Arg., 1993, 81, 127-132.
27. Neres, J.; Bryce; R. A.; Douglas, K.T. Rational drug design in parasitology: trans-sialidase as case study for Chagas's disease. Drug Discov. Today, 2008, 13, 110-117.
28. Gutierrez-Correa, J.; Fairlamb, A.H.; Stoppani, A.O. Trypanosoma cruzi trypanothione reductase is inactivated by peroxidasegenerated phenothiazine cationic radicals. Free Radic. Res., 2001, 34, 363-378.
29. Rivarola, H.W.; Paglini-Oliva, P.A. Trypanosoma cruzi trypanothione reductase inhibitors: phenothiazines and related compounds modify experimental Chagas' disease evolution. Curr. Drug. Target Cardiovasc. Haematol. Disord., 2002, 2, 43-52.
30. Salmon-Chemin, L.; Buisine, E.; Yardley, V.; Kohler, S.; Debreu, M-A.; Landry, V.; Sergheraert, C.; Croft, S.L.; Krauth-Siegel, R.L.; Davioud-Charvet, E. 2- and 3-substituted 1,4-naphtoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from Trypanosoma cruzi: synthesis and correlation between redox cycling activities and in vitro cytotoxicity. J. Med. Chem., 2001, 44, 548-565.
31. Lo Presti, M.S.; Rivarola, H.W., Bustamante J.M.; Fernandez, A.R.; Enders, J.E.; Fretes, R.; Gea, S.; Paglini-Oliva, P.A. Thioridazine treatment prevents cardiopathy in Trypanosoma cruzi infected mice. Int. J. Antimicrob. Agents, 2004, 23, 634-636.
32. Garzoni, L.R.; Caldera, A.; Meirelles, M.N.L.; Britto, C.; Docampo, R.; Oldfield, E.; Urbina, J. A. Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Int. J. Antimicrob. Agents, 2004, 23, 286-290.
33. Freymann, D.M; Wenck, M.A.; Engel, J.C.; Feng, J.; Focia, P.J.; Eakin, A.E.; Craig, S. P. Efficient identification of inhibitors targeting the closed active site conformation of HPRT from Trypanosoma cruzi. Chem. Biol., 2000, 7, 957-968.
34. Lopes, N.P.; Chicaro, P.; Kato, M.J.; Albuquerque, S.; Yoshida, M. Flavonoids and lignans from Virola surinamensis twigs active against Trypanosoma cruzi in vitro. Planta Med., 1998, 64, 667-669.
35. De Souza, V.A.; da Silva, R.; Pereira, A.C.; Royo, V.A.; Saraiva, J.; Montanheiro, M.; de Souza, G.H.B.; Filho, A.A.S.; Grando, M.D.; Donate, P.M.; Bastos, J.K.; Albuquerque, S.; Silva, M. L.A. Trypanocidal activity of (-)-cubebin derivatives against free amastigote forms of Trypanosoma cruzi. Bioorg. Med. Chem. Lett., 2005, 15, 303-307.
36. See: http://www.who.int/malaria/docs/TreatmentGuidelines 2006.pdf
37. Ibezin, E.C.; Odo. U. Current trends in malarial chemotherapy. Afr. J. Biotechnol., 2008, 7, 349-356.
38. Winstanley, P.A. Chemotherapy for Falciparum Malaria. The Armoury, the Problems and the Prospects. Parasitol. Today, 2000, 16, 146-153.
39. Ridley, R.G.; Hudson, A.T. Chemotherapy of malaria. Curr. Opin. Infect. Dis., 1998, 11, 691-706.
40. See http://www.cdc.gov/malaria/travel/drugs-hcp.htm
41. See http://www.dndi.org.
42. Wesche, D.L.; Schuster, B.G.; Wang, W.X.; Woosley, R.L.; Mechanism of cardiotoxicity of halofantrine. Clin. Pharmacol. Ther., 2000, 67 521-529.
43. See http://www.gsk.com/media/pressreleases/2008/2008-pressre lease-0014. htm.
44. Biot, C.; Glorian, G.; Maciejewski, L.A.; Brocard, J.S.; Synthesis and antimalarial activity in vitro and in vivo of a new ferrocenechloroquine analogue. J. Med. Chem., 1997, 40, 3715-3718.
45. Shanks, G.D.; Oloo, A.J.; Aleman, G.M.; Ohrt, C.; Klotz, F.W.; Braitman, D.; Horton, J.; Brueckner, R. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin. Infect. Dis., 2001, 33, 1968-1974.
46. See: http://clinicaltrials.gov/ct2/show/NCT00323375
47. R-G, Sandhya; Catz, P.; Creek, M.; Wu, B.; Thomas, D.; Krogstad, D.; De, D.; Mirsalis, J.; Green, C. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques. Int. J. Toxicol., 2004, 23, 179-189.
48. University of Liverpool; Park, B.K.; O'Neill, P.M.; Ward, S.A.; Stocks, P.A.; Anti-malarial compounds. World Patent number WO02072554, 2002.
49. See http://www.mmv.org/article.php3?id-article=47
50. Nicolas, O.; Margout, D.; Taudon, N.; Wein, S.; Calas, M.; Vial, H.J.; Bressolle, F.M.M. Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3. Antimicrob. Agents Chemother., 2005, 49, 3631-3639.
51. Thanh, N.X.; Trung, T.N.; Phong N.C.; Thien N.X.; Dai. B.; Shanks G.D.; Chavchich, M.; Edstein M.D. Open label randomized comparison of dihydroartemisinin-piperaquine and artesunateamodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam. Trop. Med. Int. Health, 2009, 14, 504-511.
52. See http://www.mmv.org/article.php3?id-article=52.
53. Tjitra, E.; Ruangweerayut, R.; Socheat, D.; Valecha, N. Treatment of acute Plasmodium vivax malaria with Pyramax (r) (pyronaridine tetraphosphate/artesunate) in a controlled phase III clinical trial. Am. J. Trop. Med. Hygiene 2008, 79, 255-255.
54. See http://www.mmv.org/article.php3?id-article=48.
55. Missinou, M.A.; Borrmann, S.; Schindler, A.; Issifou, S.; Adegnika, A.A.; Matsiegui, P-B.; Binder, R.; Lell, B.; Wiesner, J.; Baranek, T.; Jomaa, H.; Kremsner, P.G. Fosmidomycin for malaria. Lancet, 2002, 360, 1941-1942.
56. Chandra, R.; Lewis, D.; Moran, D.; Dubhashi, N.; Sarkar, S.; Wang, C.S.; Cai, J.; Dunne, M. A Phase 2, open label, noncomparative trial of azithromycin 2g plus chloroquine 600 mg base daily for three days for the treatment of uncomplicated Plasmodium falciparum malaria. Am. J. Trop. Med. Hygiene 2008, 79, 110-110.
57. See http://media.pfizer.com/files/research/pipeline/2009-0331/pipeline -2009-0331.pdf.
58. Coslédan, F.; Fraisse, L.; Pellet, A.; Gillou, F.; Mordmüller, B.; Kremsner, P.G.; Moreno, A.; Mazier, D.; Maffrand, J-P.; Meunier, B. Selection of a trioxaquine as an antimalarial drug candidate. Proc. Nat. Acad. Sci. USA, 2008, 105, 17579-17584.
59. Singh C.; Pandeya, S.; Kushwahab, A.K.; Puri, S. New functionalized 1,2,4-trioxepanes: synthesis and antimalarial activity against multi-drug resistant P. yoelii in mice. Bioorg. Med. Chem. Lett., 2008, 18, 5190-5193.
60. Singh, C.; Pandey, S.; Sharma M.; Puri S.K. Orally active 1,2,4-trioxepanes: synthesis and antimalarial activity of a series of 7-arylvinyl-1,2,4-trioxepanes against multidrug-resistant Plasmodium yoelii in Swiss mice. Bioorg. Med. Chem., 2008, 15, 1816-1821.
61. Opsenica, I.; Opsenica, D.; Lanteri, C.A.; Anova, L.; Milhous, W.K.; Smith, K.S. New chimeric antimalarials with 4-Aminoquinoline moiety linked to a tetraoxane skeleton. J. Med. Chem., 2008, 51, 6216-6219.
62. Terzić, N.; Opsenica, D.; Milić, D.; Tinant, B.; Smith, K.S.; Milhous, W.K.; Solaja, B.A. Deoxycholic acid-derived tetraoxane antimalarials and antiproliferatives. J. Med Chem., 2007, 50, 5118-5127.
63. Ellis, G.L.; Amewu, R.; Sabbani, S.; Stocks, P.A.; Shone, A.; Stanford, D.; Gibbons, P.; Davies, J.; Vivas, L.; Charnaud, S.; Bongard, E.; Hall, C.; Rimmer, K.; Lozanom, S.; Jesús, M.; Gargallo, D.; Ward, S. A.; O'Neill, P.M. Two-step synthesis of achiral dispiro-1,2,4,5-tetraoxanes with outstanding antimalarial activity, low toxicity, and high-stability profiles. J. Med. Chem., 2008, 51, 2170-2177.
64. Posner, G.H.; Chang, W.; Hess, L., Woodard, L.; Sinishtaj, S.; Usera, A. R.; Maio, W.; Rosenthal, A.S.; Kalinda, A.S.; D'Angelo, J.G.; Petersen, K.S.; Stohler, R.; Chollet, J.; Santo-Tomas, J.; Snyder, C.; Rottmann, M.; Wittlin, S.; Brun, R.; Shapiro, T.A. Malariainfected mice are cured by oral administration of new artemisinin derivatives. J. Med. Chem., 2008, 51, 1035-1042.
65. Benoit-Vical, F.; Lelièvre, J.; Berry, A.; Deymier, C.; Dechy-Cabaret, O.; Cazelles, J.; Loup, C.; Robert, A.; Magnaval, J.F.; Meunier, B. Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. Antimicrob. Agents Chemother., 2007, 51, 1463-1472.
66. Chou, A.C.; Chevli, R.; Fitch, C.D. Ferriprotoporphyrin IX fulfills the criteria for identification as the chloroquine receptor of malaria parasites. Biochemistry, 1980, 19, 1543-1549.
67. Sparatore, A.; Basilico, N.; Casagrande, M.; Parapini, S.; Taramelli, D.; Brun, R.; Wittlin, S.; Sparatore, F. Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline. Bioorg. Med. Chem. Lett., 2008, 18, 3737-3740.
68. Fattorusso, C.; Campiani, G.; Kukreja, G.; Persico, M.; Butini, S.; Romano, M.P.; Altarelli, M,; Ros, S.; Brindisi, M.; Savini, L.; Novellino, E.; Nacci, V.; Fattorusso, E.; Parapini, S.; Basilico, N.; Taramelli, D.; Yardley, V.; Croft, S.; Borriello, M.; Gemma, S. Design, synthesis, and structure-activity relationship studies of 4-quinolinyl- and 9-acrydinylhydrazones as potent antimalarial agents. J. Med. Chem., 2008, 51, 1333-1343.
69. Solomon, V.R.; Haq, W.; Srivastava, K.; Puri, S.K.; Katti, S.B. Synthesis and antimalarial activity of side chain modified 4-aminoquinoline derivatives. J. Med. Chem., 2007, 50, 394-398.
70. Kaur, K.; Patel, S.R.; Patil, P.; Jain, M.; Khan, S.I.; Jacob, M.R.; Ganesan. S.; Tekwani, B.L.; Jain, R. Synthesis, antimalarial, antileishmanial, antimicrobial, cytotoxicity, and methemoglobin (MetHB) formation activities of new 8-quinolinamines. Bioorg. Med. Chem., 2007, 15, 915-930.
71. Jain, M.; Vangapandu, S.; Sachdeva, S.; Singh, S.; Singh, P.P.; Jena, G.B.; Tikoo, K.; Ramarao, P.; Kaul, C.L.; Jain, R. Discovery of a bulky 2-tert-butyl group containing primaquine analogue that exhibits potent blood-schizontocidal antimalarial activities and complete elimination of methemoglobin toxicity. J. Med. Chem., 2004, 47, 285-287.
72. Yeates, C.L.; Batchelor, J.F.; Capon, E.C.; Cheesman, N.J.; Fry, M.; Hudson, A. T.; Pudney, M.; Trimming, H.; Woolven, J.; Bueno, J.M.; Chicharro, J.; Fernández, E.; Fiandor, J.M.; Gargallo-Viola, D.; Gómez de las Heras, F.; Herreros, E.; León, M.L. Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials. J. Med. Chem., 2008, 51, 2845-2852.
73. Barazarte, A.; Camacho, J.; Domínguez, J.; Lobo, G.; Gamboa, N.; Rodrigues, J.; Capparelli, M.V.; Alvarez-Larena, A.; Andujar, S.; Enriz, D.; Charris, J. Synthesis, antimalarial activity, structureactivity relationship analysis of thieno-[3,2-b]benzothiazine S,Sdioxide analogs. Bioorg. Med. Chem., 2008, 16, 3661-3674.
74. Gemma, S.; Campiani, G.; Butini, S.; Kukreja, G.; Coccone, S.S.; Joshi, B.P.; Persico, M.; Nacci, V.; Fiorini, I.; Novellino, E.; Fattorusso, E.; Taglialatela-Scafati, O.; Savini, L.; Taramelli, D.; Basilico, N.; Parapini, S.; Morace, G.; Yardley, V.; Croft, S.; Coletta, M.; Marini, S.; Fattorusso, C. Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies. J. Med. Chem., 2008, 51, 1278-1294.
75. Kumar, S.; Das, S.K.; Dey, S.; Maity, P.; Guha, M.; Choubey, V.; Panda, G.; Bandyopadhyay, U. Antiplasmodial activity of [(aryl)arylsulfanylmethyl]- pyridine. Antimicrob. Agents Chemother., 2008, 52, 705-715.
76. Zhu, S.; Zhang, Q.; Gudise, C.; Meng, L.; Wei, L.; Smith, E.; Kong Y. Synthesis and evaluation of naphthyridine compounds as antimalarial agents. Bioorg. Med. Chem. Lett., 2007, 17, 6101-6106.
77. Takasu, K.; Pudhom, K.; Kaiser, M.; Brun, R.; Ihara, M. Synthesis and antimalarial efficacy of aza-fused rhodacyanines in vitro and in the P. berghei mouse model. J. Med. Chem., 2006, 49, 4795-4798.
78. Hamzé, A.; Rubi, E.; Arnal, P.; Boisbrun, M.; Carcel, C.; Salom-Roig, X.; Maynadier, M.; Wein, S.; Vial, H.; Calas, M. Mono- and bis-thiazolium salts have potent antimalarial activity. J. Med. Chem., 2005, 48, 3639-3643.
79. Salom-Roig, X.J.; Hamzé, A.; Calas, M.; Vial, H.J. Dual molecules as new antimalarials. Comb. Chem. High Throughput Screen., 2005, 8, 49-62.
80. Osa, Y.; Kobayashi, S.; Sato, Y.; Suzuki, Y.; Takino, K.; Takeuchi, T.; Miyata, Y.; Sakaguchi, M.; Takayanagi, H. Structural properties of dibenzosuberanylpiperazine derivatives for efficient reversal of chloroquine resistance in Plasmodium chabaudi. J. Med. Chem., 2003, 46, 1948-1956.
81. Cattand, P.; Jannin, J.; Lucas, P. Sleeping sickness surveillance: an essential step towards elimination. Trop. Med. Int. Health, 2001, 6, 348-631.
82. World Health Organisation. Human African Trypanosomiasis (sleeping sickness): epidemiological update. Wkly. Epidemiol. Rec., 2006, 8, 69-80.
83. Legros, D.; Ollivier, G,; Gastellu-Etchegorry, M.; Paquet, C.; Burri, C.; Jannin, J.; Büscher, P. Treatment of human African trypanosomiasis - present situation and needs for research and development. Lancet Infect. Dis., 2002, 2, 437-440.
84. See http://www.immtechpharma.com/documents/news-122607. pdf.
85. See http://www.immtechpharma.com/documents/news-122607. pdf.
86. Kolocouris, N; Zoidis, G; Foscolos, G. B.; Fytas, G, Prathalingham, R.S.; Kelly, J.M.; Naesens, L.; Clercq, E. Design and synthesis of bioactive adamantane spiro heterocycles. Bioorg. Med. Chem. Lett., 2007, 17, 4358-4362.
87. Papanastasiou, I.; Tsotinis, A.; Kolocouris, S.; Prathalingam, S. R.; Kelly, J. M. Design, synthesis, and trypanocidal activity of new aminoadamantane derivatives. J. Med. Chem., 2008, 51, 1496-1500.
88. Huyanga, T.L.; Bacchi, C.J.; Kide, N.R.; Zhang, Q.; Wang, G.; Yartlet, N.; Rattendi, D.; Londono, I.; Mazumder, L.; Eynde, J.J.V.; Mayencea, A.; Donkor, I.O. Trypanocidal activity of piperazine-linked bisbenzamidines and bisbenzamidoxime, an orally active prodrug. Int. J. Antimicrob. Agents, 2007, 30, 555-561.
89. Mallari, J.P.; Shelat, A.; Kosinski, A.; Caffrey, C.R.; Connelly, M.; Zhu, F.; McKerrow, J.H.; Guy, R.K. Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorg. Med. Chem. Lett., 2008, 18, 2883-2885.
90. Mallari, J.P.; Shelat, A.A.; Obrien, T.; Caffrey, C.R.; Kosinski, A.; Connelly, M.; Harbut, M.; Greenbaum, D.; McKerrow, J.H.; Guy, R.K. Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. J. Med. Chem., 2008, 51, 545-552.
91. Balliani, A.; Bueno, G.J.; Stewart, M.L.; Yardley, V.; Brun, R.; Barrett, M.P.; Gilbert, I.H. Design and synthesis of a series of melamine-based nitroheterocycles with activity against trypanosomatid parasites. J. Med. Chem., 2005, 48, 5570-5579.
92. Nkemngu, N.J.; Grande, R.; Hansell, E.; McKerrow, J.H.; Caffrey, C.R.; Steverding, D. Improved trypanocidal activities of cathepsin L inhibitors. Int. J. Antimicr. Agents, 2003, 22, 155-159.
93. See http://www.who.int/tdr/dw/leish2004.htm.
94. St. George, S.; Bishop, J.V.; Titus, R.G.; Selitrennikoff, C.P. Novel compounds active against Leishmania major. Antimicrob. Agents Chemother., 2006, 50, 474-479.
95. See http://www.who.int/leishmaniasis/en
96. Croft, S.L.; Coombs, G.H. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol., 2003, 19, 502-508.
97. Patel, J.A.; Shah, K. Leishamniasis: A Review. Pharmacol. Online, 2008, 2, 1-11.
98. See http:/www.who.ch
99. Gradoni, L.; Gramiccia, M. Leishmania infantum tropism - strain genotype or host immune status. Parasitol. Today, 1994, 10, 264-267.
100. Bernardino, A.M.R.; Gomes, A.O.; Charret, K.S.; Freitas, A.C.C.; Machado, G.M.C.; Canto-Cavalheiro, M.M.; Leon, L.L.; Amaral, V.F. Synthesis and leishmanicidal activities of 1-(4-X-phenyl)-N-[(4-Y-phenyl)methylene]-1H- pyrazole-4-carbohydrazides. Eur. J. Med. Chem., 2006, 41, 80-87.
101. Rabello, A.; Orsini, M.; Disch, J. Leishmania/HIV co-infection in Brazil: an appraisal. Ann. Trop. Med. Parasitol., 2003, 97, S17-S28.
102. Tasdemir, D.; Kaiser, M.; Brun, R.; Yardley, V.; Schmidt, T.J.; Tosun, F.; Rüedi, P. Antitrypanosomal and antileishmanial activities of flavonoids and their analogues: in vitro, in vivo, structureactivity relationship and quantitative structure-activity relationship Studies. Antimicr. Agents Chemoter., 2006, 50, 1352-1364.
103. Bressi, J.C.; Verlinde, C.L.M.J.; Aronov, A.M.; Le Shaw, M.; Shin, S.S.; Nguyen, L.N.; Suresh, S.; Buckner, F.S.; Van Voorhis, W.C.; Kuntz, I.D.; Hol, W.G.J.; Gelb, M.H. Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design. J. Med. Chem., 2001, 44, 2080-2093.
104. Boiani, M.; Boiani. L.; Denicola A.; De Ortiz, S.T.; Serna, E.; De Bilbao, N.V.; Sanabria, L.; Yaluff, G.; Nakayama, H.; De Arias, A.R.; Vega, C.; Rolan, M.; Gomez-Barrio, A.; Cerecetto, H.; Gonzalez, M. 2H-benzimidazole 1,3-dioxide derivatives: a new family of water-soluble anti-trypanosomatid agents. J. Med. Chem., 2006, 49, 3215-3224.
105. Ollinaro, P.L.; Guerin, P.J.; Gerstl, S.; Haaskjold, A. A.; Rottingen, J-A.; Sundar, S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1984-2004. Lancet Infect. Dis., 2005, 5, 763-774.
106. Murray, H.W.; Berman, J.D.; Davies, C.R.; Saravia, N.G. Advances in leishmaniasis. Lancet 2005, 366, 1561-1577.
107. Guerin, J.P.; Olliaro, P.; Sundar, S.; Boelaert, M.; Croft, S.L.; Desjeux, P.; Wasunna, M.K.; Bryceson, A.D.M. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis., 2002, 2, 494-501.
108. Croft, S.L.; Engel, J. Miltefosine - discovery of the antileishmanial activity of phospholipid derivatives. Trans. R. Soc. Trop. Med. Hygiene, 2006, 100S, S4-S8.
109. Sundar, S.; Jha, T.K.; Takur, C.P.; Sinha, P.K.; Battacharya, S. T.; Injectable paromomycin for visceral leishmaniasis in India. N. Engl. J. Med., 2007, 356, 2571-2581.
110. See http://www.oneworldhealth.org/about/history.php.
111. See http://www.gsk.com/investors/product-pipeline/pp.htm
112. See http://www.gsk-clinicalstudyregister.com/index.jsp
113. Croft, S.L.; Seifert, K.; Yeardley, V. Current scenario of drug development for leishmaniasis. Ind. J. Med. Res., 2006, 123, 399-410.
114. Seeberger, J.; Daoud, S.; Pammer, J. Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Intl. J. Dermatol., 2003, 42, 576-579.
115. Buates, S. and Matlashewski, G. Treatment of experimental leishmaniasis with the immunomodulators Imiquimod and S-28463: Efficacy and Mode of Action. J. Infect. Dis., 1999, 179, 1485-1494.
116. Al-Abdely, H.M.; Graybill, J.R.; Loebenberg, D.; Melby, P.C. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrob. Agents Chemother., 1999, 43, 2910-2914.
117. Zhai, L.; Chen, M.; Blom, J.; Theander, T.; Christensen, S. B.; Kharazmi, A. The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J. Antimicrob. Chemother., 1999, 43, 793-803.
118. Silva, E.F.; Canto-Cavalheiro, M.M.; Braz, V.R.; Cysne-Finkelstein, L.; Leon, L.L.; Echevarria, A. Synthesis, and biological evaluation of new 1,3,4-thiadiazolium-2-phenylamine derivatives against Leishmania amazonensis promastigotes and amastigotes. Eur. J. Med. Chem., 2002, 37, 979-984.
119. Bazin, M.A.; Loiseau, P.M.; Bories, C.; Letourneux, Y.; Rault, S.; El Kihel, L. Synthesis of oxysterols and nitrogenous sterols with antileishmanial and trypanocidal activities. Eur. J. Med. Chem., 2006, 41, 1109-1116.